1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (2021-2027)
  • 1.2.2 Chemotherapy Drug
  • 1.2.3 Monoclonal Antibody
  • 1.2.4 Kinase Inhibitor
  • 1.2.5 CAR T-cell Therapy
  • 1.2.6 Others
• 1.3 Market by Application
  • 1.3.1 Global Follicular Lymphoma Drugs Market Share by Patient Age (2021-2027)
  • 1.3.2 < 55
  • 1.3.3 55-64
  • 1.3.4 65+
• 1.4 Study Objectives
• 1.5 Years Considered

2 Executive Summary

• 2.1 Global Follicular Lymphoma Drugs Market Size
• 2.2 Follicular Lymphoma Drugs Market Size by Regions
  • 2.2.1 Follicular Lymphoma Drugs Growth Rate by Regions (2021-2027)
  • 2.2.2 Follicular Lymphoma Drugs Market Share by Regions (2021-2027)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Use Cases

3 Key Players

• 3.1 Follicular Lymphoma Drugs Revenue by Players (2020-2021)
• 3.2 Follicular Lymphoma Drugs Key Players Headquaters and Area Served
• 3.3 Key Players Follicular Lymphoma Drugs Product/Solution/Service
• 3.4 Date of Enter into Follicular Lymphoma Drugs Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown by Type and by Patient Age

• 4.1 Global Follicular Lymphoma Drugs Market Size by Type (2021-2027)
• 4.2 Global Follicular Lymphoma Drugs Market Size by Patient Age (2021-2027)

5 North America

• 5.1 North America Follicular Lymphoma Drugs Market Forecast (2021-2027)
• 5.2 Follicular Lymphoma Drugs Key Players in North America
• 5.3 North America Follicular Lymphoma Drugs Market Size by Type
• 5.4 North America Follicular Lymphoma Drugs Market Size by Patient Age
  • 6.4.4 Canada

6 Europe

• 6.1 Europe Follicular Lymphoma Drugs Market Forecast (2021-2027)
• 6.2 Follicular Lymphoma Drugs Key Players in Europe
• 6.3 Europe Follicular Lymphoma Drugs Market Size by Type
• 6.4 Europe Follicular Lymphoma Drugs Market Size by Patient Age

7 Japan

• 7.1 Japan Follicular Lymphoma Drugs Market Forecast (2021-2027)
• 7.2 Follicular Lymphoma Drugs Key Players in Europe
• 7.3 Japan Follicular Lymphoma Drugs Market Size by Type
• 7.4 Japan Follicular Lymphoma Drugs Market Size by Patient Age

8 Rest of World

• 8.1 China
  • 8.1.1 China Follicular Lymphoma Drugs Market Analysis
  • 8.1.2 Key Players in China
• 8.2 Southeast Asia
  • 8.2.1 Southeast Asia Follicular Lymphoma Drugs Market Analysis
  • 8.2.2 Key Players in Southeast Asia
• 8.3 India
  • 8.3.1 India Follicular Lymphoma Drugs Market Analysis
  • 8.3.2 Key Players in India

9 International Player Profiles

• 9.1 Genentech (Roche)
  • 9.1.1 Genentech (Roche) Company Details
  • 9.1.2 Genentech (Roche) Description and Business Overview
  • 9.1.3 Genentech (Roche) Follicular Lymphoma Drugs Introduction
  • 9.1.4 Genentech (Roche) Revenue in Follicular Lymphoma Drugs Business (2020-2021)
  • 9.1.5 Genentech (Roche) Recent Development
• 9.2 Bristol-Myers Squibb
  • 9.2.1 Bristol-Myers Squibb Company Details
  • 9.2.2 Bristol-Myers Squibb Description and Business Overview
  • 9.2.3 Bristol-Myers Squibb Follicular Lymphoma Drugs Introduction
  • 9.2.4 Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business (2020-2021)
  • 9.2.5 Bristol-Myers Squibb Recent Development
• 9.3 Gilead Sciences
  • 9.3.1 Gilead Sciences Company Details
  • 9.3.2 Gilead Sciences Description and Business Overview
  • 9.3.3 Gilead Sciences Follicular Lymphoma Drugs Introduction
  • 9.3.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2020-2021)
  • 9.3.5 Gilead Sciences Recent Development
• 9.4 TG Therapeutics
  • 9.4.1 TG Therapeutics Company Details
  • 9.4.2 TG Therapeutics Description and Business Overview
  • 9.4.3 TG Therapeutics Follicular Lymphoma Drugs Introduction
  • 9.4.4 TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2020-2021)
  • 9.4.5 TG Therapeutics Recent Development
• 9.5 Bayer
  • 9.5.1 Bayer Company Details
  • 9.5.2 Bayer Description and Business Overview
  • 9.5.3 Bayer Follicular Lymphoma Drugs Introduction
  • 9.5.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2020-2021)
  • 9.5.5 Bayer Recent Development
• 9.6 Secura Bio
  • 9.6.1 Secura Bio Company Details
  • 9.6.2 Secura Bio Description and Business Overview
  • 9.6.3 Secura Bio Follicular Lymphoma Drugs Introduction
  • 9.6.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2020-2021)
  • 9.6.5 Secura Bio Recent Development
• 9.7 Epizyme
  • 9.7.1 Epizyme Company Details
  • 9.7.2 Epizyme Description and Business Overview
  • 9.7.3 Epizyme Follicular Lymphoma Drugs Introduction
  • 9.7.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2020-2021)
  • 9.7.5 Epizyme Recent Development
• 9.8 Jazz Pharmaceuticals
  • 9.8.1 Jazz Pharmaceuticals Company Details
  • 9.8.2 Jazz Pharmaceuticals Description and Business Overview
  • 9.8.3 Jazz Pharmaceuticals Follicular Lymphoma Drugs Introduction
  • 9.8.4 Jazz Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2020-2021)
  • 9.8.5 Jazz Pharmaceuticals Recent Development

10 Market Dynamics

• 10.1 Industry Trends
• 10.2 Market Drives
• 10.3 Market Challenges
• 10.4 Market Restraints

11 Key Findings in This Report

12 Appendix

• 12.1 Research Methodology
  • 12.1.1 Methodology/Research Approach
  • 12.1.2 Data Source
• 12.2 Disclaimer

Global Follicular Lymphoma Drugs Scope and Market Size
Follicular Lymphoma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Follicular Lymphoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Patient Age in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy Drug
Monoclonal Antibody
Kinase Inhibitor
CAR T-cell Therapy
Others

Segment by Patient Age
< 55
55-64
65+

By Region
North America
Europe
Japan
China
Southeast Asia
India

By Company
Genentech (Roche)
Bristol-Myers Squibb
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Jazz Pharmaceuticals